
Revelation Biosciences, Inc.
REVBHealthcare|Biotechnology|US
$3.89
+0.33 (+9.27%)
DCF Value
$106.03
Tangible Book / Share
$12.93
Cash / Share
$16.30
About
Revelation Biosciences, Inc. is a biopharmaceutical firm currently in its clinical development phase, dedicated to the advancement and commercialization of treatments and diagnostic tools targeting the immune system. The company's therapeutic pipeline includes promising candidates such as GEM-AKI, which is being developed as a potential therapy for both the prevention and management of acute kidney injury, and GEM-CKD, intended for the prevention and treatment of chronic kidney disease. Established in 2019, this San Diego, California-based enterprise was formerly known as Petra Acquisition, Inc., before officially adopting the name Revelation Biosciences, Inc. in January 2022.
Stock Price
-86.2%(1Y)
1M
-28.2%
3M
-51.3%
6M
-42.1%
YTD
-82.6%
1Y
-86.6%
3Y
-100.0%
5Y
-100.0%
Pipeline Summary
1 total trials1
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
Completed: 1
Key Facts
Market Cap$2.2M
Employees8 (+0% YoY)
CEOJames Rolke
IPO DateNov 17, 2020
Beta-0.17
52-Week Range$3.08 – $40.6
Avg Volume10,275
ExchangeNASDAQ
Websiterevbiosciences.com
Ownership
Float76.5%
Shares Outstanding0.6M
Recent Insider Trades
Rolke JamesAWARD
Aug 17, 2026208,076 shares
Chawla Lakhmir SAWARD
Aug 17, 202632,011 shares
Zygmont Chester Stanley IIIGIFT
Aug 17, 2026208,073 shares
Zygmont Chester Stanley IIIAWARD
Aug 17, 2026208,073 shares
Zygmont Chester Stanley IIIGIFT
Aug 17, 2026208,073 shares
Peers
Recent News
Revelation Biosciences, Inc. Announces Financial Results For the Three and Nine Months Ended September 30, 2026
Nov 5, 2026 · businesswire.com
Revelation Biosciences Announces 1-for-7 Reverse Stock Split Effective October 20, 2026
Oct 16, 2026 · gurufocus.com
Revelation Biosciences Announces 1-for-7 Reverse Stock Split Effective October 20, 2026
Oct 16, 2026 · businesswire.com
Revelation Biosciences Selects Avance Clinical as CRO for Phase 2/3 TITAN Study
Aug 19, 2026 · businesswire.com
Data last updated: Nov 9, 2026, 04:31 AM